Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

June 15, 2007 (Vol. 27, No. 12)

BioMarket Trends: Genomics & Impending Market Revolutions

The Holiest Grail, Personalized Medicine, Is Likely to Advance Incrementally

  • Life sciences companies that participate in the U.S. genomics market constantly struggle to exploit opportunities surrounding the impending revolutions of personalized medicine, molecular diagnostics, pharmacogenomics, and the $1,000 genome. These companies are under great pressures to execute effective growth strategies while confronting tremendous hype in an industry fraught with ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.